Ron Bose

This study shows that HER2 and TP53 co-mutant cancers have increased histone acetylation and are sensitive to neratinib plus trastuzumab deruxtecan.

This paper develops a mouse model of HER2-positive breast cancer cerebellar metastases and identifies IL34-induced Arg1+ macrophages as key drivers of tumor growth, showing that targeting CSF1R can reduce metastases.

This study identifies breast cancer subtypes and their lineage origins by analyzing chromatin accessibility and transcriptional dynamics using multi-omic techniques.

The paper tests neratinib combinations with T-DM1 and vinorelbine in HER2 mutated breast cancer PDX models and organoids, finding synergistic effects that could inform clinical trials.

The paper identifies somatic mutations with prognostic effects in ER+ breast cancer using genomic data from multiple cohorts.

CIViC is a knowledgebase that crowdsources expert input to interpret the clinical significance of cancer variants, providing open-access resources for precision medicine.